Additionally, resistance mechanisms include the PI3K/AKT/mTOR pathway, which is dysregulated in 22% of BRAF inhibitor-resistant melanomas characterized by increased expression of the AKT protein [36]. This evidence concerns the gene AKT1 and melanoma.